Completed PHASE3 INTERVENTIONAL 1-arm NCT01908816

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (ECLIPSE)

Sponsor: Novartis Pharmaceuticals

Conditions Choroidal Neovascularization Diabetic Retinopathy Glaucoma, Neovascular Macular Edema

Interventions ranibizumab

Updated 8 times since 2017 Last updated: Jul 2, 2019 Started: Sep 26, 2013 Primary completion: Jan 8, 2016 Completion: Jan 8, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Choroidal Neovascularization and Diabetic Retinopathy and is currently completed. Novartis Pharmaceuticals leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Sep 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Angers, France , Bobigny, France , Bordeaux, France , Caen, France , Créteil, France , Grenoble, France , Lille, France , Lyon, France , Mantes-la-Jolie, France and 18 more locations